We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 12

Legal trends '13: a forecast of the year ahead - life sciences

  • Blake Cassels & Graydon LLP
  • -
  • Canada
  • -
  • January 17 2013

The Supreme Court of Canada (SCC) held Pfizer's patent for the use of sildenafil, commercially known as Viagra, void for failing to adequately

Proposed amendments to the Patents Act and other intellectual property related acts

  • Wong Partnership
  • -
  • Singapore
  • -
  • August 16 2012

To strengthen our existing patent regime and further develop our intellectual property (“IP”) infrastructure in response to the growth in the demand for IP, the Ministry of Law and the Intellectual Property Office of Singapore (“IPOS”) recently tabled the Patents (Amendment) Bill and the Intellectual Property (Miscellaneous Amendments) Bill before Parliament on 14 May 2012

Patenting business methods after Mayo

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • July 30 2012

Advances in information technology, such as high-performance computing, enables the collection, analysis and sharing of information between patients and medical providers

Supreme Court on health reform and patent case budget transportation programs FCC reform cybersecurity

  • Edwards Wildman Palmer LLP
  • -
  • USA
  • -
  • April 5 2012

With a two-week recess looming and the 2012 elections coming ever more into focus, Congress addressed a temporary fix on a critical deadline and set the stage for the budget debate, tax reform and other key considerations to be taken up over the Spring and Summer as it completed its most recent work period late last week

Federal Court of Canada grants data protection to an old medicinal ingredient

  • Torys LLP
  • -
  • Canada
  • -
  • February 14 2012

In a recent decision Celgene Inc. v. Canada (Minister of Health) the Federal Court of Canada declared that a drug containing a previously approved medicinal ingredient is nevertheless subject to data protection

Ip snapshot - September 2011

  • CMS Cameron McKenna
  • -
  • United Kingdom
  • -
  • September 30 2011

Mr Justice Floyd has granted an application for an expedited trial in favour of Teva, in circumstances in which, if Teva succeeds in invalidating Warner-Lambert’s patent, Teva may obtain an advantage over other generic manufacturers of the drug atorvastatin, marketed by Warner-Lambert as Lipitor, one of the world’s most successful drugs with an annual turnover exceeding £350 million

Noteworthy cases in the United States Supreme Court’s 2011 term

  • Larkin Hoffman
  • -
  • USA
  • -
  • September 21 2011

The first Monday in October represents the start of a new term for the United States Supreme Court

Control at issue in split Federal Circuit ruling on joint infringement

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 21 2011

A divided Federal Circuit Court of Appeals panel, relying on recent precedent, has confirmed that "where the actions of multiple parties combine to perform every step of a claimed method, the claim is directly infringed only if one party exercises 'control or direction' over the entire process such that every step is attributable to the controlling party."

Evaluating life sciences inventions: surveying patents similar to assessing real estate

  • Pillsbury Winthrop Shaw Pittman LLP
  • -
  • USA
  • -
  • March 29 2011

Pillsbury Life Sciences team co-head Dr. John Wetherell explains why evaluating the worth of intangible IP in this sector is not all that different from assessing the value of real property

Federal Court of Appeal upholds the Data Protection Regulations and its guaranteed eight-year period of market exclusivity for "innovative drugs"

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • January 21 2011

The Federal Court of Appeal has upheld the validity of section 30(3) of the Food and Drugs Act and section C.08.004.1 of the Food and Drug Regulations (known as the Data Protection Regulations) in its decision in Apotex Inc. v. The Minister of Health, 2010 FCA 334

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy